The microbiome is recognized as a new frontier in medicine with connections to a variety of diseases.
This report
explains the role for lipopolysaccharide (LPS) in the pathogenesis and
severity of structural abnormalities and symptoms of knee osteoarthritis (OA)
efficiently. LPS is an important product of microbiome which is concerned with
the variety of diseases.
The microbiome is
recognized as a new frontier in medicine with connections to a variety of
diseases. We aimed to evaluate the association of lipopolysaccharide (LPS), a
key pro-inflammatory product of the microbiome, with severity of inflammation,
symptoms and radiographic abnormalities of knee osteoarthritis (OA).
LPS was measured
using a recombinant Factor C (rFC) assay, carefully optimized for systemic and
synovial fluid (SF) analyses. LPS binding protein (LBP) was tested in both
serum and SF of 25 patients (31 knees) from the Etarfolatide cohort for
association with OA phenotypic outcomes. Models were adjusted for age, gender
and body mass index.
Based on LPS
spike-and-recovery, both serum and SF dilutions of 0.1% were required to
achieve recovery rates of at least 75% in all test specimens. Low coefficients
of variation (CVs) (<10%) were achieved with both serum and SF dilutions
<0.2%. Serum LPS and LBP were associated with the abundance of activated
macrophages in the knee joint capsule and synovium. SF LPS and LBP were
associated with the abundance of activated macrophages in the synovium. Serum
LPS, LBP and SF LPS were associated with knee osteophyte severity. SF LPS was
positively associated with knee joint space narrowing (JSN) severity and total
WOMAC score. SF LBP was positively associated with self-reported knee pain
score.
These data
strongly support a role for LPS in the pathogenesis and severity of structural
abnormalities and symptoms of knee OA.
Osteoarthritis Cartilage 2016 May 20
Both systemic and local lipopolysaccharide (LPS) burden are associated with knee OA severity and inflammation
Z.Y. Huang
Comments (0)